Evidence map›Paper›PMID 28673852›Full record

ArticleNanomedicine : nanotechnology, biology, and medicine2017

Effective encapsulation and biological activity of phosphorylated chemotherapeutics in calcium phosphosilicate nanoparticles for the treatment of pancreatic cancer.

Welley S Loc, Samuel S Linton, Zachary R Wilczynski, Gail L Matters, Christopher O McGovern, Thomas Abraham, Todd Fox, Christopher M Gigliotti, Xiaomeng Tang, Amra Tabakovic and 6 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine : nanotechnology, biology, and medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Tailor-Made Nanomaterials for Diagnosis and Therapy of Pancreatic Ductal Adenocarcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021
    Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Welley S LocDepartment of Chemistry, Pennsylvania State University, University Park, PA, USA; Department of Materials Science and Engineering, Pennsylvania State University, University Park, PA, USA.
Samuel S LintonDepartment of Pharmacology, Pennsylvania State University College of Medicine, Hershey, PA, USA.
Zachary R WilczynskiDepartment of Biomedical Engineering/Bioengineering, Pennsylvania State University, University Park, PA, USA.
Gail L MattersDepartment of Biochemistry and Molecular Biology, Pennsylvania State University College of Medicine, Hershey, PA, USA.
Christopher O McGovernDepartment of Biochemistry and Molecular Biology, Pennsylvania State University College of Medicine, Hershey, PA, USA.
Thomas AbrahamDepartment of Neural and Behavioral Sciences and the Microscopy Imaging Facility, Pennsylvania State University College of Medicine, Hershey, PA, USA.
Todd FoxDepartment of Pharmacology, University of Virginia, Charlottesville, VA, USA.
Christopher M GigliottiDepartment of Biomedical Engineering/Bioengineering, Pennsylvania State University, University Park, PA, USA.
Xiaomeng TangDepartment of Chemistry, Pennsylvania State University, University Park, PA, USA; Department of Materials Science and Engineering, Pennsylvania State University, University Park, PA, USA.
Amra TabakovicDepartment of Materials Science and Engineering, Pennsylvania State University, University Park, PA, USA.
Jo Ann MartinBiomedical Engineering, University of Florida, Gainesville, FL, USA.
Gary A ClawsonDepartment of Pathology and Gittlen Cancer Institute, Pennsylvania State University College of Medicine, Hershey, PA, USA.
Jill P SmithDepartment of Medicine, Georgetown University, Washington, DC, USA.
Peter J ButlerDepartment of Biomedical Engineering/Bioengineering, Pennsylvania State University, University Park, PA, USA.
Mark KesterDepartment of Pharmacology, University of Virginia, Charlottesville, VA, USA.
James H AdairDepartment of Materials Science and Engineering, Pennsylvania State University, University Park, PA, USA; Department of Pharmacology, Pennsylvania State University College of Medicine, Hershey, PA, USA; Department of Biomedical Engineering/Bioengineering, Pennsylvania State University, University Park, PA, USA. Electronic address: jha3@ems.psu.edu.
Pennsylvania State University · USUniversity of Virginia · USGeorgetown University · USUniversity of Florida · US

Funding

Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Thomas P. Loughran · 1987 to 2026
$72.1M
Penn State Clinical and Translational Science InstituteUL1TR002014 · NCATS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI KRASCHNEWSKI, JENNIFER L. · 2016 to 2025
$33.7M
Penn State Clinical and Translational Science InstituteUL1TR000127 · NCATS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI SINOWAY, LAWRENCE I · 2012 to 2015
$17.1M
NRSA Training CoreTL1TR002016 · NCATS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI THOMAS, GAIL D. · 2016 to 2025
$3.4M
Novel Nanoparticle Therapy for Pancreatic CancerR01CA167535 · NCI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI KESTER, MARK, MATTERS, GAIL L. · 2013 to 2017
$1.6M
Penn State Clinical and Translational Science InstituteTL1TR000125 · NCATS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI SINOWAY, LAWRENCE I · 2012 to 2015
$550k
Targeting Pancreatic Cancer with Aptamers to the CCK-B ReceptorR21CA170121 · NCI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI MATTERS, GAIL L. · 2013 to 2014
$361k
NCATS NIH HHS TL1 TR000125NCATS NIH HHS TL1 TR002016NCATS NIH HHS UL1 TR000127NCATS NIH HHS UL1 TR002014NCI NIH HHS P30 CA044579NCI NIH HHS R01 CA167535NCI NIH HHS R21 CA170121
6 · The paper itself

Abstract

Drug resistant cancers like pancreatic ductal adenocarcinoma (PDAC) are difficult to treat, and nanoparticle drug delivery systems can overcome some of the limitations of conventional systemic chemotherapy. In this study, we demonstrate that FdUMP and dFdCMP, the bioactive, phosphorylated metabolites of the chemotherapy drugs 5-FU and gemcitabine, can be encapsulated into calcium phosphosilicate nanoparticles (CPSNPs). The non-phosphorylated drug analogs were not well encapsulated by CPSNPs, suggesting the phosphate modification is essential for effective encapsulation. In vitro proliferation assays, cell cycle analyses and/or thymidylate synthase inhibition assays verified that CPSNP-encapsulated phospho-drugs retained biological activity. Analysis of orthotopic tumors from mice treated systemically with tumor-targeted FdUMP-CPSNPs confirmed the in vivo up take of these particles by PDAC tumor cells and release of active drug cargos intracellularly. These findings demonstrate a novel methodology to efficiently encapsulate chemotherapeutic agents into the CPSNPs and to effectively deliver them to pancreatic tumor cells.

Indexed as

AnimalsAntineoplastic AgentsCalcium CompoundsCarcinoma, Pancreatic DuctalCell Cycle CheckpointsCell Line, TumorCell ProliferationDeoxycytidineDrug CarriersDrug Delivery SystemsFluorouracilGemcitabineHumansMaleMiceMice, NudeAntineoplastic AgentsCalcium Compoundscalcium silicateDeoxycytidineDrug CarriersFluorouracilGemcitabineSilicates5-FluorouracildFdCMPFdUMPGemcitabineNanodelivery

Identifiers

PMID28673852
PMCPMC5625839
OpenAlexW2728551359

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.